38-OR: Clinical relevance of luminex donor-specific crossmatches: Data from 165 renal transplants

Abstract

Aim: The clinical significance of the presence of donor-specific anti-HLA antibodies prior to renal transplantation detected solely by solid-phase techniques remains unclear. This study was designed to determine the clinical relevance (acute rejection Ͻ6 months, graft survival) of the recently introduced beadbased Luminex donor-specific crossmatch (LumXm).Methods: A group of 165 patients transplanted with a negative CDCXm between 1997 and 2001, with median follow-up of 8 years was tested.Results: 32 of 165 had a positive LumXm: 16 were positive for class I, 15 for class II, one was both class I and II positive.133 recipients were negative. Acute rejection-free survival (Kaplan-Meier) for all recipients was 77%, there was no difference between LumXm positive and negative recipients. Overall graft survival after a median follow-up time of 8 years was 56%. Recipients with a positive class I LumXm had worse 10-year graft survival: 27% vs 56% (pϭ0.006). Positivity for class II LumXm was not a significant risk factor for graft failure (pϭ0.7).Conclusions: In conclusion pre-transplant donor-specific anti-HLA antibodies detected by LumXm, had no correlation with acute rejection episodes. A positive class I LumXm resulted in worse long-term graft survival compared to a negative one.